Crescent Biopharma, Inc.

NASDAQ:CBIO

Biotechnology

Healthcare
$12.40 -2.69%

-$0.49 today

Market cap
$482.30M
Beta
1.15
P/E (TTM)
-3.3
EPS (TTM)
-$5.33
52W Low $8.72High $27.41

Volume 0.33M

Average 0.28M

CBIO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Crescent Biopharma, Inc.NASDAQ: CBIO

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$23.22M, compared with -$14.04M a year earlier. Trailing-twelve-month EBITDA was -$158.86M.

Context

  • EBITDA amounted to 1380.2% of revenue in FY2025.
  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of -$33.68M (+77.5%) for the fiscal year ending Dec 2026, a step up from the -238.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$23.22M+74.3% QoQ
Last fiscal yearDec 2025
-$149.67M-238.8% YoY
LTMMar 2026
-$158.86M-1227.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-65.4%-38.4%+27.0 pp
1 year-238.8%+77.5%+316.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(149.67M) USD
Year-over-year change
-238.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1227.0% is the lowest of 10, against a peer median of -25.2%.
  • EBITDA amounts to 1336.8% of revenue for CBIO, versus a peer median of 105.1%.
CBIO Competitors
EBITDA for CBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$57.08M USD+205.8%—21.5%
CGENCompugen Ltd.LTM Mar 2026$34.88M USD+463.6%—48.0%
NBPNovaBridge BiosciencesLTM Sep 2025-CN¥33.25M CNY+92.9%——
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.18M USD-45.5%——
MGNXMacroGenics, Inc.LTM Mar 2026-$50.64M USD-7.0%—32.2%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-$57.67M USD-232.5%—162.2%
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$67.05M USD-25.2%——
CBIOCrescent Biopharma, Inc.LTM Mar 2026-$158.86M USD-1227.0%—1336.8%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$305.37M USD-38.1%—272652.7%
RCUSArcus Biosciences, Inc.LTM Jun 2026-$419M USD-48.6%—358.1%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CBIO) —-25.2%—105.1%

Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.16M75K10K010.84M
Cost of Revenue00000
Gross Profit1.16M75K10K010.84M
Gross Margin100.0%100.0%100.0%—100.0%
Research & Development47.49M28.39M20.07M28.06M138.09M
Selling, General & Admin17.12M19.09M19.21M16.32M25.39M
Operating Expenses64.61M47.48M39.29M49.9M163.48M
Depreciation & Amortization264.6K207.15K153.3K35.17K84K
EBITDA(63.18M)(47.2M)(39.12M)(44.17M)(149.67M)
EBITDA Margin-5447.9%-62927.6%-391213.5%—-1380.2%
Operating Income(63.45M)(47.4M)(39.28M)(49.9M)(152.63M)
Operating Margin-5470.7%-63204.4%-392752.9%—-1407.5%
Interest Income19.77K714.52K2.38M1M2.88M
Interest Expense000852K2.19M
Other Income / Expenses19.77K714.96K2.38M1.37M690K
Income Before Tax(63.43M)(46.69M)(36.9M)(48.52M)(151.94M)
Pre-Tax Margin-5469.0%-62251.1%-368987.8%—-1401.2%
Income Tax Expense00002M
Net Income(63.43M)(46.69M)(36.9M)(48.52M)(153.94M)
Net Margin-5469.0%-62251.7%-368994.2%—-1419.6%
EPS (Basic)(1.23)(0.89)(0.58)(1.40)(14.78)
EPS (Diluted)(1.23)(0.89)(0.58)(1.40)(14.78)
Weighted Avg Shares51.45M52.53M63.34M19.5M10.41M
Weighted Avg Shares (Diluted)51.45M52.53M63.34M19.5M10.41M

Crescent Biopharma, Inc.

NASDAQ:CBIO

Intrinsic Alpha fair value

Locked

Current Price

$12.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.